Abstract
Background:
While substance abuse among psychiatric patients is a widely known problem in clinical practice, there is no local study about prevalence and co-occurrence of substance abuse in north of Iran.Objectives:
The present study was designed to determine the frequency of smoking, alcohol, opioid and cannabinoid substances, and prescription medicines abuse or dependence among Psychiatric Inpatients.Patients and Methods:
A cross-sectional 2-year case register study was conducted on all (n = 492) psychiatric inpatients of Zare Psychiatric Hospital in Sari located in north of Iran. The data were obtained by using a standardized and validated questionnaire that contained demographic information along with information on co-morbid psychiatric problems and alcohol, cannabinoids, opioids, and cigarette usage.Results:
The mean (± SD) age of samples was 39.9 (± 11.9) years and male:female ratio was 3.6. Opium with or without using other illicit substances was the most frequently abused substance (67%). Significant association were found between illicit substance abuse and demographic variables of male gender, a low level of literacy, living in the urban area, unemployment, cigarette smoking, and young age. There were statistically significant association between schizophrenia and substance abuse (P < 0.001).Conclusion:
High prevalence of dual diagnosis warrants attention to the management of substance misuse while treating mental disorders, and should be incorporated in the holistic treatment plan of psychiatric inpatients.Keywords
Behavior Addictive Diagnosis Dual Psychiatry Substance Abuse Intravenous
1. Background
Substance abuse among psychiatric patients is a widely known problem. Although the precise extent and detail of this phenomenon is unclear (1), in recent decades vast majority of studies reported a high rate of co-occurrence of substance use disorders with psychiatric disorders (2). Numerous epidemiological surveys have found high rates of substance misuse among psychiatric patients. This co-occurrence, which is also called dual diagnosis, contributes to poorer motivation and treatment compliance as well as outcomes (3).
Dual diagnosis is the term used to describe patients with both severe mental illness (mainly psychotic disorders) and problematic drug and or alcohol use. The term originated from the United States in the 1980s and has been adopted in the United Kingdom and other countries more recently. The nature of the relationship between the two conditions is complex and sometimes controversial (4).
A primary psychiatric illness may trigger or lead to substance misuse and this phenomenon may worsen or change the outcome of a psychiatric illness. On the other hand, substance misuse and or withdrawal may result in psychiatric symptoms or illness. It may also act as a trigger or precipitating factor in those predisposed to mental illness (5).
Research studies have indicated that at least one-half of the patients in psychiatric or substance misuse treatment centers have been diagnosed with co-morbid psychiatric and substance use disorders (6).
Many studies have shown high prevalence of alcohol abuse among patients with depression and some have found increasing opiates use in schizophrenia (7). This is clinically important as this co-morbidity has a negative impact on the treatment of both conditions (3). While many different epidemiological factors contribute to this phenomenon, inconsistent results have been observed in different studies (8). As a result, the findings could not be generalized to other societies and even to a certain disease.
Iran because of its vicinity to Afghanistan, the biggest world supply of opium, has a high exposure rate to opium and its derivatives and accordingly there are more reports of opiate dependency (9).
2. Objectives
Considering the importance of substance use among psychiatric patients and its effect on the recovery process emphasized in numerous studies, the present study was designed to determine (a) the frequency of smoking, alcohol, opioid and cannabinoid substances, and prescription medicines abuse or dependence, and (b) types of psychiatric disorders in patients with substance abuse.
3. Patients and Methods
A cross-sectional 2-year case register study was conducted on all adult (> 18 years) psychiatric inpatients (n = 492) of Zare Psychiatric Hospital in Sari, Mazandaran, a northern province of Iran at the southern border of Caspian Sea. The patients were evaluated by conducting a structured interview and completing a questionnaire to record demographic, and disease-related information. It also contained detailed information on the type and pattern of alcohol, smoking, and two most prevalent drugs of abuse in Iran (opioid and cannabinoid substances). To complete the assessment process collateral information were also obtained from family members and patients’ hospital case files.
The questionnaire consisted of 27 items collecting data on the demographic characteristics (8 questions), psychiatric co-morbidities (5 questions), and substance/drug abuse/dependence (14 questions). The questionnaire had been designed by the researchers and validated by peer review and a pilot study (Cronbach α = 0.92).
The psychiatric diseases were diagnosed and confirmed by using clinical information according to the DSM-IV-TR criteria (10). Urine test was performed to detect opioid and cannabinoid substances recently used using the Sure Step TM kits (Applied Biotech Inc.). Statistical Package for the Social Sciences (SPSS - v14) free version was used to analyze the data by using descriptive statistics and measures of association (Pearson and chi-square).
4. Results
The mean ± SD age of samples was 39.9 ± 11.9 years and male:female ratio was 3.6 (385 men vs. 107 women).
More than 60% (n = 307) of the patients were living in the city. Approximately 60% (n = 294) of the patients were unemployed, and 95.7% (n = 471) had high school diploma or a lower educational degree. Over half of the patients (n = 253) were married and 8.9% (n = 44) were divorced. The most frequent observed psychiatric disorder was schizophrenia (36.6%) (Table 1).
The mean ± SD disease duration was 104 ± 11.3 months, (95% CI, 103.02-104.98) and mean ± SD hospitalization rate was 2.5 ± 0.4 times (95% CI, 2.46-2.53).
According to urine test, the rate of current substance abuse or dependence in all patients was about 52.2%. In addition, there were 238 (46.6%) current smoker patients in the sample. The mean age onset of smoking was 20.5 (± 3.4) years. Lifetime abuse or dependence rate in all psychiatric inpatients has been shown in Table 2. Prescription medicines abuse or dependence prevalence was 7.5% (n = 37). Benzodiazepines were the most misused group (in all 37 patients) either alone or in combination with other medicines. Antidepressants took the second place with 31% and anticholinergic agents with 20% took the third place.
According to urine test, current opioid and cannabinoid substances or prescription medicines abuse or dependence was reported in 130 patients (26.4%). According to the questionnaire results, prevalence of lifetime abuse or dependence among hospitalized psychiatric patients was more than half (n = 257, 52.2%) with nearly 158 (32.1%) of these patients having the history of at least one substance abuse (Table 2).
Opium with or without other substances was the most frequent substance abused in 67% of cases (Table 3). The mean ± SD age of onset for substances use was 22.2 ± 2.8, (95% CI, 22.16-22.23) and mean ± SD rate for abstinence was 2 ± 0.4. Family pressure was reported as the main reason for quitting substance misuse.
Schizophrenia and mood disorders were the two most common psychiatric disorders in substance abuser or dependent inpatients, but schizophrenia had a statistically significant association with substance misuse or dependence (P < 0.001) (Table 4).
We also found a significant association of opioid and cannabinoid substances abuse or dependence with many demographic factors like male gender, lower educational achievement, living in the city, unemployment, and younger age (Table 5).
Finally, we found strong association between current smoking and opioid-cannabinoid substances abuse or dependence (P < 0.001, χ2 = 32.23). We also found that substance abuse or dependence started approximately 2 years after patients began smoking.
| Variables | Female | Male | Total |
|---|---|---|---|
| Schizophrenia | 34 (6.9) | 146 (29.7) | 180 (36.6) |
| Bipolar disorder | 39 (7.9) | 90 (18.3) | 129 (26.2) |
| MDD with or without PF | 20 (4.1) | 40 (8.1) | 60 (12.2) |
| Substance induced mood disorders | 1 (0.2) | 38 (7.7) | 39 (7.9) |
| Other psychotic disorders | 9 (1.8) | 22 (4.5) | 31 (6.3) |
| Personality disorders | 1 (0.2) | 15 (3.0) | 16 (3.3) |
| Other psychiatric disorders | 3 (0.6) | 34 (6.9) | 37 (7.5) |
| Substance/medicines of abuse/dependence | Values |
|---|---|
| 45 (9.1) | |
| 37 (7.5) | |
| 158 (32.1) | |
| 238 (48.4) | |
| 235 (47.8) |
| Substance | Opium | Hashish | Heroin | Grass |
|---|---|---|---|---|
| Female | 3 (2.2) | 1 (0.7) | 0 (0) | 1 (0.7) |
| Male | 84 (64.7) | 60 (46.2) | 29 (22.3) | 18 (13.7) |
| Total | 87 (67) | 61 (47) | 29 (22.3) | 19 (14.5) |
Association of Psychiatric Disorders With Current Substance Abuser/Dependency a
| Abuse | Urine Test | P Value | χ2 | |
|---|---|---|---|---|
| Positive | Total | |||
| Schizophrenia | 34 | 180 | 0.000 | 17.71 |
| Bipolar disorder | 34 | 129 | 0.257 | 1.28 |
| MDD with or without PF† | 12 | 60 | 0.195 | 0.375 |
| Other psychotic disorders | 10 | 31 | 0.936 | 5.28 |
| Personality disorders | 9 | 16 | 0.171 | 0.72 |
| Other psychiatric disorders | 10 | 37 | 0.005 | 6.72 |
Association Between Demographic Characteristics and Current Substance Abuse
| Demographic variables | P Value | χ2 |
|---|---|---|
| 0.000 | 29.21 | |
| 0.001 | 9.84 | |
| 0.025 | 7.78 | |
| 0.000 | 22.65 | |
| 0.004 | 16.42 |
5. Discussion
Substance abuse has been reported in association with various medical conditions. Research has shown a considerable tobacco and opium dependence with the rate of 44.2% and 5.8% for heart diseases and 17.9% and 7.1% for pulmonary diseases, respectively (11). This phenomenon has been reported in many other medical diseases, including rheumatologic diseases (12) and hemophilia (13).
In our study, the rate of substance abuse in the psychiatric inpatients was higher than the rate of this co-morbidity that has been reported in the literature in association with any other medical condition. This may be due to the nature of psychiatric problems and therefore needs more attention during the treatment process (14).
Although we found an association of substance dependence with two groups of psychiatric disorders, only in one of these, i.e. schizophrenia, the association was statistically significant and in the second group (other psychiatric disorders, containing a large number of non-specific psychiatric disorders), it was not.
In our study the smoking rate was approximately three times higher than what has been reported in the general population (15). Smoking in psychiatric patients increases the activity of P450 system in the liver and CYP1A2 enzymes, thus decreases the blood concentration of many antipsychotic drugs and their side effects, which might be rewarding for the patients (16). Our study also found a strong relationship between smoking and substance abuse event prior to the onset of psychiatric disorders.
There are many differences in the type of substance abuse or dependence and specific psychiatric disorders and their association in the literature. Studies have shown a different pattern of substance abuse or dependence in Iran compared to the rest of the world. These differences are partly cultural and partly due to the availability of substances in this part of the world. For example, raw opium dependence is quite common because Iran is a neighbor to Afghanistan which is the main producer of this substance in the world (17). Opioids are the primary drugs of abuse in Iran. Two different forms of opioid abuse afflict Iran; heroin injection and opium smoking and ingestion (18). Indigenous raw opium accounts for 69% to 94.6% of total opioid use in this country (16). Cannabinoid substances are the second prevalent drugs of abuse in Iran (19).
There are a number of reasons why patients with dual diagnosis do not receive the necessary care. These reasons include lack of treatment access, high cost of treatment, stigmatization, treating only mental illness or substance use disorders in separation, as well as a medical care system that do not put enough emphasis on the recognition or treatment of a co-morbid substance misuse and also a medical education system that dedicate very little training or teaching time to this significant area of clinical practice (7).
The results of our study revealed a high prevalence of co-morbid substance misuse in psychiatric inpatients, which has a significant impact on the management of both conditions. In this respect, we recommend that the protocol for the management of psychiatric illnesses in psychiatric hospitals be revised so that the early recognition and management of co-morbid substance misuse are more emphasized.
In addition, a strong association of smoking and substance misuse has been noted in our study. This association with high rate of substance misuse warrants further studies on how public education about harmful effect of cigarette smoking can help reduce the overall rate of substance dependency in the general population.
Acknowledgements
References
-
1.
Katz G, Shufman E, Knobler HY, Joffe M, Bar-Hamburger R, Durst R. [Drug abuse among patients requiring psychiatric hospitalization]. Harefuah. 2000;138(12):1015-8. 1088. [PubMed ID: 10979421].
-
2.
Brady KT, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry. 2005;162(8):1483-93. [PubMed ID: 16055769]. https://doi.org/10.1176/appi.ajp.162.8.1483.
-
3.
Havassy BE, Alvidrez J, Owen KK. Comparisons of patients with comorbid psychiatric and substance use disorders: implications for treatment and service delivery. Am J Psychiatry. 2004;161(1):139-45. [PubMed ID: 14702262].
-
4.
Cook R. The Dual Diagnosis Strategy. Sussex: NHS Foundation Trust; 2009.
-
5.
The National Service Framework for Mental Health. State So; 1999.
-
6.
Results from the 2005 National Survey on Drug Use and Health: National Findings. Rockville MD: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2006.
-
7.
Greenfield SF, editor. Epidemiology and Course of Co-Occurring Alcohol Use and Depressive Disorders. AAAP ANNUAL MEETING SYMPOSIUM VI. 2000.
-
8.
Wusthoff LE, Waal H, Ruud T, Grawe RW. A cross-sectional study of patients with and without substance use disorders in Community Mental Health Centres. BMC Psychiatry. 2011;11:93. [PubMed ID: 21605358]. https://doi.org/10.1186/1471-244X-11-93.
-
9.
Agahi C, Spencer CP. Drug abuse in pre- and post-revolutionary Iran. J Psychoactive Drugs. 1981;13(1):39-46. [PubMed ID: 7277087]. https://doi.org/10.1080/02791072.1981.10471449.
-
10.
Diagnostic and Statistical Manual of Mental Disorders. 4th ed. United States: American Psychiatric Association; 2000.
-
11.
Ahmadi J, Soltani F, Tabatabaee F, Gozin Z, Ahmadi S, Ahmadi F, et al. Substance Use Disorders in Patients with Lung or Heart Diseases. Sch J App Med Sci. 2014;2(1A):111-20.
-
12.
Ahmadi J, Pridmore S. Substance Use Disorders in Rheumatic Patients. German J Psychiatry. 2005;5:66-9.
-
13.
Karimi M, Hashemi A, Ghiam AF, Jahromi SS, Toobaee S. Substance dependency in Iranian patients with hemophilia. Addict Behav. 2007;32(2):365-9. [PubMed ID: 16707228]. https://doi.org/10.1016/j.addbeh.2006.03.040.
-
14.
Hasin DS, Grant BF. The co-occurrence of DSM-IV alcohol abuse in DSM-IV alcohol dependence: results of the National Epidemiologic Survey on Alcohol and Related Conditions on heterogeneity that differ by population subgroup. Arch Gen Psychiatry. 2004;61(9):891-6. [PubMed ID: 15351767]. https://doi.org/10.1001/archpsyc.61.9.891.
-
15.
Jamshidi Ardeshiri M, Moosazadeh M, Feizi Masouleh M, Feizi Masouleh M, Kiani A, Fakhri M. Prevalence of smoking in 15-64 years old population of north of Iran: meta-analysis of the results of non-communicable diseases risk factors surveillance system. Acta Med Iran. 2013;51(7):494-500. [PubMed ID: 23945896].
-
16.
Razzaghi E, Rahimi A, Hosseini M, Chatterjee A. Rapid Situation Assessment (RSA) of drug abuse in Iran. Prevention Department, State Welfare Organization, Ministry of Health, IR of Iran and United Nations International Drug Control Program; 1999.
-
17.
Trovato GM, Martines GF, Garozzo A, Tonzuso A, Timpanaro R, Pirri C, et al. Ad36 adipogenic adenovirus in human non-alcoholic fatty liver disease. Liver Int. 2010;30(2):184-90. [PubMed ID: 19840251]. https://doi.org/10.1111/j.1478-3231.2009.02127.x.
-
18.
Mokri A. Brief overview of the status of drug abuse in Iran. Arch Iranian Med. 2002;5(3):184-90.
-
19.
Statistics on Drug abuse in Iran. Tehran: The Ministry; 2000.